Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
IRCCS Azienda Ospedaliero-Universitaria di Bologna
With
Ospedale SS Giovanni e Paolo, Venezia
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients ≥ 18 years old
Diagnosis of histologically confirmed advanced epithelial ovarian carcinoma
Women eligible for treatment with a chemotherapy regimen in combination to bevacizumab (Cohort A)
Women eligible for treatment with a chemotherapy regimen not associated to antiangiogenic drugs (Cohort B)
Evaluable disease according to RECIST 1.1 criteria
Patient informed consent signature prior to any study-specific procedure
You may not be if
History of other malignancy within 5 years prior to study entry (except for cutaneous basal cell carcinoma or adequately treated carcinoma in situ of the cervix ).
Clareo Health | Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
